362 related articles for article (PubMed ID: 32643507)
1. PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential.
Yang T; Kong Z; Ma W
Hum Vaccin Immunother; 2021 Feb; 17(2):546-553. PubMed ID: 32643507
[TBL] [Abstract][Full Text] [Related]
2. Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions.
Maghrouni A; Givari M; Jalili-Nik M; Mollazadeh H; Bibak B; Sadeghi MM; Afshari AR; Johnston TP; Sahebkar A
Int Immunopharmacol; 2021 Apr; 93():107403. PubMed ID: 33581502
[TBL] [Abstract][Full Text] [Related]
3. Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma.
Wang X; Guo G; Guan H; Yu Y; Lu J; Yu J
J Exp Clin Cancer Res; 2019 Feb; 38(1):87. PubMed ID: 30777100
[TBL] [Abstract][Full Text] [Related]
4. Investigation of the relationship between immune checkpoints and mismatch repair deficiency in recurrent and nonrecurrent glioblastoma.
Çakır E; Saygın İ; Ercin ME
Turk J Med Sci; 2021 Aug; 51(4):1800-1808. PubMed ID: 33600097
[TBL] [Abstract][Full Text] [Related]
5. Combination immunotherapy strategies for glioblastoma.
Chan HY; Choi J; Jackson C; Lim M
J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
[TBL] [Abstract][Full Text] [Related]
6. Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
Schatz J; Ladinig A; Fietkau R; Putz F; Gaipl US; Frey B; Derer A
Strahlenther Onkol; 2023 Dec; 199(12):1140-1151. PubMed ID: 36480032
[TBL] [Abstract][Full Text] [Related]
7. Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma.
Shu C; Li Q
Crit Rev Oncol Hematol; 2020 Jul; 151():102965. PubMed ID: 32442903
[TBL] [Abstract][Full Text] [Related]
8. Application prospect of peptide-modified nano targeting drug delivery system combined with PD-1/PD-L1 based immune checkpoint blockade in glioblastoma.
Song P; Zhao X; Xiao S
Int J Pharm; 2020 Nov; 589():119865. PubMed ID: 32919004
[TBL] [Abstract][Full Text] [Related]
9. Metabolism/Immunity Dual-Regulation Thermogels Potentiating Immunotherapy of Glioblastoma Through Lactate-Excretion Inhibition and PD-1/PD-L1 Blockade.
Li T; Xu D; Ruan Z; Zhou J; Sun W; Rao B; Xu H
Adv Sci (Weinh); 2024 May; 11(18):e2310163. PubMed ID: 38460167
[TBL] [Abstract][Full Text] [Related]
10. Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma.
Sanders S; Debinski W
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316096
[TBL] [Abstract][Full Text] [Related]
11. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
Maxwell R; Jackson CM; Lim M
Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
[TBL] [Abstract][Full Text] [Related]
12. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
13. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J
JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895
[TBL] [Abstract][Full Text] [Related]
14. Artificial neural network identified a 20-gene panel in predicting immunotherapy response and survival benefits after anti-PD1/PD-L1 treatment in glioblastoma patients.
Wang Y; Wang Z; Guo X; Cao Y; Xing H; Wang Y; Xing B; Wang Y; Yao Y; Ma W
Cancer Med; 2024 May; 13(9):e7218. PubMed ID: 38733169
[TBL] [Abstract][Full Text] [Related]
15. PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review.
Caccese M; Indraccolo S; Zagonel V; Lombardi G
Crit Rev Oncol Hematol; 2019 Mar; 135():128-134. PubMed ID: 30819441
[TBL] [Abstract][Full Text] [Related]
16. Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma.
Iorgulescu JB; Gokhale PC; Speranza MC; Eschle BK; Poitras MJ; Wilkens MK; Soroko KM; Chhoeu C; Knott A; Gao Y; Lim-Fat MJ; Baker GJ; Bonal DM; Nguyen QD; Grant GRL; Ligon KL; Sorger PK; Chiocca EA; Anderson AC; Kirschmeier PT; Sharpe AH; Freeman GJ; Reardon DA
Clin Cancer Res; 2021 Jan; 27(1):276-287. PubMed ID: 33239433
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY
Front Immunol; 2018; 9():727. PubMed ID: 29910795
[TBL] [Abstract][Full Text] [Related]
18. The path forward for anti-programmed cell death-1 therapy in gliomas.
Majd N; Kamiya-Matsuoka C; de Groot J
Curr Opin Neurol; 2019 Dec; 32(6):864-871. PubMed ID: 31567548
[TBL] [Abstract][Full Text] [Related]
19. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
20. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
